Hong Kong: Expanded Licensing Regime For Asset Managers Managing OTC Derivatives Transactions

  • Amended Hong Kong Securities and Futures Ordinance expands existing type 9 Regulated Activity (Asset Management) to cover management of OTC derivative products.
  • A Type 9 licenseholder managing OTC derivative products will be required to apply to the SFC and to meet new assessment criteria for such products (experience, internal compliance procedures), or will be required to close out of positions and/or discontinue existing OTC derivatives business.

Background

Following a two year consultation period, the SFC issued a Circular in October 2015 ("Circular") setting out an expanded licensing regime covering over-the-counter ("OTC") derivative transactions and products1 ("Expanded OTC Regime").

Amongst other regulatory changes summarized in the Circular is the SFC's conclusion that certain activities relating to OTC derivatives (such as the management of OTC derivatives) are to be considered as "regulated activities", and the corresponding implementation of an updated licensing regime to cover the carrying on, in Hong Kong, of such activities.

Expanded OTC Regime in Hong Kong

Under the Expanded OTC Regime, the scope of the existing regulated activity of "asset management" (資產管理) (Type 9 Regulated Activity for the purpose of the Hong Kong Securities and Futures Ordinance (Cap. 571) ("SFO") has been revised. This now provides for the expansion of the existing Type 9 license to cover asset management activities with respect to OTC derivative products (alongside the more traditional "securities and futures contracts" asset management).

At the same time, separate amendments to the SFO were made in order to create the proposed new regulated activities of "dealing or advising on OTC derivatives products" (Type 11) and "providing client clearing services for OTC derivative transactions" (Type 12), as well as to expand the scope of the existing regulated activity of "providing automated trading services" (Type 7) to cover OTC derivative transactions or products.2

What is an OTC derivative product?

In order to take account of the Expanded OTC Regime, the SFO has been substantially amended3 in order to provide for a formal definition of "OTC derivative product", and to provide for the corresponding regulatory framework.

An "OTC derivative product" (場外衍生工具產品) is defined in in Part 1B of Schedule of the SFO as a "structured product" (結構性產品) (as defined in Part 1A of Schedule of the SFO) that does not include:

  1. securities traded on a recognized exchange;
  2. futures contracts traded on a recognized exchange;
  3. securities or futures contracts that are traded through a market prescribed under section 392A of the SFO (as prescribed by the Financial Secretary) and cleared through a clearing house prescribed under that section;
  4. structured products offered to the public and authorized under the SFO;
  5. structured products that are debt securities;
  6. certain "spot contracts" (contracts for immediate delivery and payment normally two business days after the trade date ) (as defined in the SFO);
  7. certain structured products that are offered within a two-week offer period and on identical terms; and
  8. structured products formally classified by notice issued by the Financial Secretary as falling outside of the definition of an OTC derivative product.

In addition, the Financial Secretary of Hong Kong has the power to determine, by notice, a product as being regarded as an OTC derivative product.

In practice, OTC derivative products will include over-the-counter instruments such as futures, swaps, options and other derivatives which fall outside of the "excluded items" listed in the SFO.

Why is this relevant to an existing Type 9 licenseholder?

The Expanded OTC Regime will introduce an enhanced regulatory regime for Type 9 licenseholders undertaking asset management with respect to OTC derivative products

With effect from commencement date (to be announced by the SFC, but expected to be during late 2016/early 2017) (the "Commencement Date"), licensed corporations wishing to engage in the management of OTC derivative products will be required to be licensed for the expanded Type 9 Regulated Activity. This will require the filing of an application with the SFC in order to avoid the automatic imposition of a license condition that the licensed corporation may not manage OTC derivative products.

For new Type 9 applicants wishing to manage OTC derivative products, this will require the applicant to demonstrate to the SFC that it satisfies the SFC's additional requirements for the Expanded OTC Regime.

How will the SFC implement the Expanded OTC Regime?

The SFC has prescribed a six month grace period from the Commencement Date ("Transitional Period") in order to allow existing Type 9 licensed corporations to:

  1. apply to the SFC to register for the expanded Type 9 Regulated Activity (i.e., to allow the manager to undertake asset management with respect to OTC derivative products); or
  2. manage out of existing positions and to wind up any OTC derivatives management activities (if any).

During the Transitional Period, market participants may continue to manage OTC derivative products without the need for an additional license/registration. However, immediately upon the expiry of the Transitional Period, existing licensed corporations will no longer be able to manage portfolios of OTC derivative products, unless:

  1. they have applied to the SFC (within the first three months of the Transitional Period (the "Application Period")) to register for the expanded Type 9 Regulated Activity (subject to an initial screening, and meeting minimum specified criteria (see below) an applicant will be deemed by SFC will be "deemed to be licensed for the expanded activity"), and
  2. the SFC has subsequently approved the expanded Type 9 Regulated Activity for that licensed corporation.

Application Process

Existing Type 9 licensed corporations which wish to continue to perform activities that constitute the new or expanded Type 9 RA (i.e., management of a portfolio of OTC derivative products) ("New Type 9 activities") must file a notice with the SFC during the Application Period:

  1. stating the intention to continue with such activities;
  2. providing a detailed business plan of the New Type 9 regulated activities, internal controls and operational procedures pertaining to such business (including human and technical resources), organizational structure, contingency plans and related matters; and
  3. confirming that it employs at least one (1) Type 9 Responsible Officer in Hong Kong who has accrued a minimum of two (2) years of Hong Kong or overseas experience in New Type 9 Activities within the six (6) year period immediately prior to the Commencement Date, and that it complies, or has arrangements in place to ensure compliance, with the new requirements under the SFO, related Codes and Guidelines that are or will be applicable to the related OTC derivatives activities.

Each Type 9 Responsible Officer ("RO") of such a licensed corporation will also be required to file a prescribed notice to the SFC within the Application Period, confirming that he/she has satisfied the relevant experience requirement.

Deeming Mechanism and Assessment Criteria

A market participant that meets the SFC's specified criteria (see below) and applies for a license or registration for the New Type 9 regulated activities during the Application Period will be deemed to be licensed or registered immediately after the end of the Transitional Period, while the SFC (or the HKMA) continues to process their application. The deemed licenses or registrations will continue to have effect until the application has been approved, denied or withdrawn.

In considering an application from an existing Type 9 licensed corporation, the SFC will base its assessment on the following criteria:

  1. Experience Requirements: corporate applicants and their proposed ROs should demonstrate that they have been carrying on a business in the new or expanded regulated activity in Hong Kong for at least two (2) years immediately prior to the commencement date of the OTC derivatives licensing regime.
  2. Existing Licensing and Regulatory Requirements: all existing licensing and regulatory requirements will be generally applicable to corporate applicants and their proposed ROs, e.g. the requirements for at least two (2) ROs for each new or expanded regulated activity, with at least one (1) RO being an executive director.
  3. Application Documents: in addition to the license or registration application documents, a corporate applicant will be required to submit a prescribed form confirming points (i) and (ii) (above), as well as confirming compliance with existing or new requirements under the SFO or the Banking Ordinance ("BO"), and related Codes and Guidelines applicable to the applicant's OTC derivative activities.

What if an applicant fails to meet the SFC's Assessment Criteria?

A Type 9 licenseholder failing to meet the SFC's specified assessment criteria will be issued with a "no-deeming notice" by the SFC. Thereafter, such persons will be required to wind down the management of OTC derivative products and to close out of any positions and/or transfer the business to another corporation, within the period of three (3) months of the date of the "no-deeming notice".

I am a Type 9 asset manager managing OTC derivative products. What should I do now?

The Commencement Date for the revised regime is expected to be announced by the SFC during late 2016/early 2017.

Upon the Commencement Date, the three (3)-month Application Period will immediately commence, during which time a Type 9 licensed corporation wishing to continue to manage OTC derivative products must submit an application to the SFC demonstrating compliance with the SFC's assessment criteria (see above).

This is a relatively short period in which to:

  1. collate and prepare evidence of the experience of the licensed corporation (and of the RO) for the purpose of meeting the SFC's minimum assessment criteria;
  2. prepare updated drafts of internal operational documents (including the compliance manual) in order to reflect compliance with these new requirements.

In order to manage the risk of this short window, we consider that it is advisable for such Type 9 licensed corporations to take steps now, in advance of the Commencement Date, to:

  1. consider the experience of the licensed corporation (and the RO) and how this might be presented to the SFC as part of an application, and to collate all required supporting materials; and
  2. consider necessary amendments to the compliance manual (and other internal operational documents) to address compliance with the new SFC requirements for the expanded Type 9 Regulated Activity.

An existing Type 9 licensed corporation that does not file a prescribed notice within the three (3) month Application Period will be automatically deemed to be subject to a license condition restricting it from managing portfolios of OTC derivatives products.

I am an asset manager managing only securities – how does this apply to me? Do I need to take any action?

For an existing Type 9 licensed corporation that does not manage (and does not intend to manage) OTC derivative products (as defined in the updated SFO), there will be no impact to the general power to undertake "securities or futures contracts" asset management.

However, with effect from the end of the Transitional Period, an existing Type 9 licensed corporation/Type 9 RO that does not file a prescribed notification form with the SFC within the Application Period will be automatically subject to the additional license condition that they may not manage OTC derivative products.

We consider that it will be advisable for such managers to:

  1. undertake a review of all current positions, in order to ensure that OTC derivative products are not being managed as part of any portfolio managed by the existing Type 9 licensed corporation; and
  2. notify portfolio managers of the additional license condition that will be imposed following the end of the Transitional Period, in order to ensure that such personnel are fully aware that providing asset management services in respect of OTC derivative products is subject to additional regulation from the end of this period, and that an additional application to the SFC would be required in order to continue to manage such instruments.

Footnotes

1. See http://www.sfc.hk/edistributionWeb/gateway/EN/circular/openFile?refNo=15EC53

2. It is intended that these developments would be addressed by way of a separate client alert.

3. By way of the Securities and Futures (Amendment) Bill 2015 – See http://www.sfc.hk/web/EN/pdf/Gazette/Ord.%20No.%2019%20of%202015%20Legco%20Brief.pdf

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions